{"meta":{"query_hash":"648732e8aed1","filters":{"venue":"Biosimilars"},"cohort_total":1,"direct_labels_cover":0,"predictions_cover":1,"exported":1,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/648732e8aed1","api":"https://metacan.xera.ac/api/v1/cohort?venue=Biosimilars"},"results":[{"id":"W2124630617","doi":"10.2147/bs.s20577","title":"Scientific factors for assessing biosimilarity and drug interchangeability of follow-on biologics","year":2011,"lang":"en","type":"article","venue":"Biosimilars","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Amgen","keywords":"Interchangeability; Drug; Medicine; Pharmacology; Business; Biosimilar; Risk analysis (engineering); Intensive care medicine; Computer science; Internal medicine","score_opus":0.15432901733991708,"score_gpt":0.32945311233849545,"score_spread":0.17512409499857837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124630617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946797,0.00081347814,0.00071937847,0.0005608752,0.0014496477,0.0005276343,0.00034915408,0.000072613024,0.0008275075],"genre_scores_gemma":[0.9931535,0.00003239744,0.006101344,0.00038859766,0.000015681335,0.000015429941,0.000035326764,0.000016367445,0.00024137206],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981504,0.0002890458,0.0004361516,0.0006302283,0.00005309603,0.0004410992],"domain_scores_gemma":[0.9984977,0.00063428585,0.00019471972,0.0004349527,0.0001781749,0.000060166985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013331734,0.00027904168,0.0004884123,0.00019213614,0.00029134197,0.00003935373,0.00030750924,0.000400411,0.00021131837],"category_scores_gemma":[0.0008168115,0.00019817971,0.0002326035,0.0002484244,0.0013623154,0.00011567304,0.00016432363,0.00024070413,0.0000038933413],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000976597,0.0016562958,0.2695998,0.00038871914,0.00054130494,0.000003305402,0.0032741711,1.3162096e-7,0.68012697,0.004854627,0.0189925,0.01958557],"study_design_scores_gemma":[0.0009547884,0.0005437481,0.077749014,0.000087972,0.0001532731,0.000003824205,0.000931576,0.000011441941,0.9044167,0.0036936665,0.011069913,0.00038408831],"about_ca_topic_score_codex":0.000020108137,"about_ca_topic_score_gemma":0.000028346009,"teacher_disagreement_score":0.22428972,"about_ca_system_score_codex":0.000031657804,"about_ca_system_score_gemma":0.000043906726,"threshold_uncertainty_score":0.8081534},"labels":[],"label_agreement":null}]}